← Back to Search

Carbonic Anhydrase Inhibitor

Methazolamide 25 mg for Open-Angle Glaucoma

Phase 4
Waitlist Available
Led By Malik Y. Kahook, MD
Research Sponsored by University of Colorado, Denver
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Males and females between 50 and 90 years old
Current diagnosis of open angle glaucoma (OAG) in both eyes
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1 (pre-dosing, then 4- and 8- hours post dosing), day 7 (pre-dosing, then 4- and 8- hours post dosing), day 14 (pre-dosing, then 4- and 8- hours post dosing)
Awards & highlights

Study Summary

This trial is testing whether methazolamide can safely and effectively lower intraocular pressure.

Who is the study for?
This trial is for English-reading men and women aged 50 to 90 with open-angle glaucoma in both eyes. It's not for those with other types of glaucoma, severe or end-stage glaucoma, or if they are pregnant or breastfeeding.Check my eligibility
What is being tested?
The study tests methazolamide tablets at doses of 25 mg and 50 mg to lower eye pressure in glaucoma patients. Participants will take one dose daily for a week, then twice daily for another week to assess effectiveness and safety.See study design
What are the potential side effects?
Methazolamide may cause side effects like fatigue, loss of appetite, taste alterations, tingling in hands or feet, diarrhea, kidney stones, and rarely blood cell disorders.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 50 and 90 years old.
Select...
I have been diagnosed with open angle glaucoma in both eyes.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1 (pre-dosing, then 4- and 8- hours post dosing), day 7 (pre-dosing, then 4- and 8- hours post dosing), day 14 (pre-dosing, then 4- and 8- hours post dosing)
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1 (pre-dosing, then 4- and 8- hours post dosing), day 7 (pre-dosing, then 4- and 8- hours post dosing), day 14 (pre-dosing, then 4- and 8- hours post dosing) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percent IOP change at each follow-up Visit
Secondary outcome measures
Body Weight Changes
Body Weight Changes
Body Weight Changes
+2 more

Trial Design

2Treatment groups
Active Control
Group I: Methazolamide 25 mgActive Control1 Intervention
Once a day [q.d] in the morning for 1 week, Twice a day [b.i.d.] in the morning and evening for 1 week
Group II: Methazolamide 50 mgActive Control1 Intervention
Once a day [q.d] in the morning for 1 week, Twice a day [b.i.d.] in the morning and evening for 1 week

Find a Location

Who is running the clinical trial?

University of Colorado, DenverLead Sponsor
1,732 Previous Clinical Trials
2,143,518 Total Patients Enrolled
Malik Y. Kahook, MDPrincipal InvestigatorUniversity of Colorado, Denver
6 Previous Clinical Trials
175 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this research encompass those aged 65 and above?

"As specified in the admission criteria, participants must be within a 50 to 90 years old age range."

Answered by AI

Is Methazolamide 25 mg a safe dosage to take on an ongoing basis?

"The safety of Methazolamide 25 mg was classified as a 3 due to the Phase 4 trial status and its existing approval."

Answered by AI

What is the current status of recruitment for this clinical trial?

"As detailed on clinicaltrials.gov, this particular study is not actively searching for participants at the moment - though it was initially posted on August 15th 2022 and last modified two days later. On the bright side, there are presently 216 other trials that could use more volunteers."

Answered by AI

What objectives is this research endeavor aiming to satisfy?

"The primary evaluation of this clinical trial, which will take place over the course of Day 1 (Pre-dosing, then 4- and 8- hours post dosing), Day 7 (Pre-dosing, then 4- and 8- hours post dosing), Day 14 (Pre-dosing, then 4"

Answered by AI

Who qualifies to be a participant in this research program?

"In order to qualify for this glaucoma clinical trial, applicants must be between the ages of 50 and 90 and have an open-angle diagnosis. This medical investigation is currently in need of 30 participants."

Answered by AI
~14 spots leftby Apr 2025